Sign In
Buy OCX
$3.20
+0 (+0%)
At Close: Sep 16, 2025
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
06:35pm, Wednesday, 02'nd Oct 2024
Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories Company Obtains Participation from New and Existing Investors, Including Strategic Partn
Oncocyte's VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
04:30pm, Monday, 12'th Aug 2024
Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., August 12, 2024 — Oncocyte
Oncocyte's VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
04:10pm, Monday, 12'th Aug 2024
IRVINE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, announced the recent publication of a case series of two kidney transplant p
OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript
01:00pm, Saturday, 10'th Aug 2024
OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript
Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results
04:05pm, Thursday, 08'th Aug 2024
Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplant IRVINE, Calif., August 8, 2024 (GLOBE NEWSWIRE) — Onc
Oncocyte Announces August Investor Conferences Participation
04:06pm, Monday, 05'th Aug 2024
IRVINE, Calif., August 5, 2024 — Oncocyte Corp.
Oncocyte Announces August Investor Conferences Participation
04:05pm, Monday, 05'th Aug 2024
IRVINE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
04:07pm, Thursday, 01'st Aug 2024
Conference Call and Webcast on Thursday, August 8, 2024 at 2:00 p.m. PT / 5:00 p.m.
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
04:05pm, Thursday, 01'st Aug 2024
IRVINE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its second quarter 2024 financial result
MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in “Take Advantage of the Moment” Episode
08:02am, Thursday, 11'th Jul 2024
HOLLAND, Mich., July 11, 2024 – MedTech Gurus, a leading podcast focused on the forefront of medical technology, featured Oncocyte Corporation (NASDAQ: OCX) CEO Josh Riggs in its latest episode, “
Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move
12:41pm, Monday, 24'th Jun 2024
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics compa
Oncocyte Appoints Andrea James as Chief Financial Officer
04:05pm, Monday, 17'th Jun 2024
IRVINE, Calif., June 17, 2024 – Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position o
Oncocyte Appoints Andrea James as Chief Financial Officer
04:05pm, Monday, 17'th Jun 2024
IRVINE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to
Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study
02:13pm, Monday, 03'rd Jun 2024
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Oncocyte's (Nasdaq: OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
04:47pm, Thursday, 30'th May 2024
IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kid
